{"id":752868,"date":"2023-04-10T12:36:51","date_gmt":"2023-04-10T16:36:51","guid":{"rendered":"https:\/\/spaceweekly.com\/?p=752868"},"modified":"2023-04-10T12:36:51","modified_gmt":"2023-04-10T16:36:51","slug":"novel-immunotherapy-agent-safe-shows-promise-against-high-risk-prostate-cancers","status":"publish","type":"post","link":"https:\/\/spaceweekly.com\/?p=752868","title":{"rendered":"Novel immunotherapy agent safe, shows promise against high-risk prostate cancers"},"content":{"rendered":"<p>A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.&#013;<br \/>\n&#013;<br \/>\n&#013;<br \/>\n Click here for original story, <a href=\"https:\/\/www.sciencedaily.com\/releases\/2023\/04\/230410123651.htm\" target=\"_blank\" rel=\"nofollow noopener\">Novel immunotherapy agent safe, shows promise against high-risk prostate cancers<\/a>&#013;<br \/>\n&#013;<br \/>\n&#013;<br \/>\nSource: ScienceDaily&#013;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a&hellip; <\/p>\n","protected":false},"author":1,"featured_media":615444,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-752868","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genaero"],"_links":{"self":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/752868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=752868"}],"version-history":[{"count":0,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/752868\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/media\/615444"}],"wp:attachment":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=752868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=752868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=752868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}